Alzheimer’s Disease (AD) presents a significant challenge to healthcare systems worldwide, with its progressive cognitive decline impacting millions. This paper explores the potential of Brain-Computer Interface (BCI) based neurofeedback therapy as a novel approach to cognitive rehabilitation for AD patients. Traditional pharmacological interventions, though widely used, are limited by efficacy and side effects. Neurofeedback, leveraging real-time neural activity feedback, offers a non-invasive alternative, stimulating neuroplasticity and self-regulation of brain activity. The integration of BCI technology allows for personalized, adaptive therapy, responding to individual patient needs. The paper reviews the complex pathophysiology of AD, emphasizing the critical roles of amyloid-beta plaques and tau protein tangles in the progression of cognitive impairment. It delves into the mechanisms of neurofeedback, its clinical applications, and the combination of BCI with neurofeedback in treating AD. Preliminary findings suggest neurofeedback can stabilize or improve cognitive functions in AD patients, distinct from the typical decline. Despite these promising results, the overall efficacy of neurofeedback in AD treatment is not yet fully established. The approach remains under scrutiny, necessitating further rigorous research and large-scale clinical trials to validate its long-term benefits and optimal protocols. The paper concludes by emphasizing the need for extensive, interdisciplinary research, including longitudinal studies and standardized protocols, to fully realize and validate the therapeutic potential of BCI-enhanced neurofeedback in managing AD across various stages of the disease.
